CD274 and melanoma: In this study, we demonstrate that antibody targeting sMIC increases the IL-2 sensing receptor IL-2Rα on NK cells, reprograms NK cell homeostatic maintenance, and enhances the therapeutic response of melanoma tumors to PD1/PDL1 blockade therapy.